tetano
Editor, Senior Moderator
Antiviral Res. 2020 Feb 27:104753. doi: 10.1016/j.antiviral.2020.104753. [Epub ahead of print] [h=1]Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus.[/h]
Qiu H[SUP]1[/SUP], Andersen H[SUP]2[/SUP], Tarbet EB[SUP]3[/SUP], Muhammad FS[SUP]2[/SUP], Carnelley T[SUP]1[/SUP], Pronyk R[SUP]1[/SUP], Barker D[SUP]1[/SUP], Kodihalli S[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Seasonal influenza causes significant morbidity and mortality around the world each year, even with the use of vaccines and antivirals. There is a need for more effective treatments for severe and hospitalized cases of influenza. In this study, we have tested the efficacy of a human plasma-derived IgG product (FLU-IGIV) against seasonal influenza in mouse and ferret models of influenza infection. FLU-IGIV successfully protected mice (100% survival) against lethal influenza infection. Also, the survival rate observed with FLU-IGIV treatment was better than the survival rate observed with oseltamivir (60% survival). FLU-IGIV significantly reduced the viral load in the lungs compared to placebo (PBS) in ferrets infected with influenza A/California/July 2009 (H1N1pdm09) virus. Overall, these studies demonstrate the efficacy of human plasma-derived FLU-IGIV in relevant animal models of influenza virus infection.
Copyright ? 2020. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Efficacy; FLU-IGIV; H1N1pdm09; Pharmacokinetics; Seasonal influenza
PMID: 32114033 DOI: 10.1016/j.antiviral.2020.104753
Qiu H[SUP]1[/SUP], Andersen H[SUP]2[/SUP], Tarbet EB[SUP]3[/SUP], Muhammad FS[SUP]2[/SUP], Carnelley T[SUP]1[/SUP], Pronyk R[SUP]1[/SUP], Barker D[SUP]1[/SUP], Kodihalli S[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Seasonal influenza causes significant morbidity and mortality around the world each year, even with the use of vaccines and antivirals. There is a need for more effective treatments for severe and hospitalized cases of influenza. In this study, we have tested the efficacy of a human plasma-derived IgG product (FLU-IGIV) against seasonal influenza in mouse and ferret models of influenza infection. FLU-IGIV successfully protected mice (100% survival) against lethal influenza infection. Also, the survival rate observed with FLU-IGIV treatment was better than the survival rate observed with oseltamivir (60% survival). FLU-IGIV significantly reduced the viral load in the lungs compared to placebo (PBS) in ferrets infected with influenza A/California/July 2009 (H1N1pdm09) virus. Overall, these studies demonstrate the efficacy of human plasma-derived FLU-IGIV in relevant animal models of influenza virus infection.
Copyright ? 2020. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Efficacy; FLU-IGIV; H1N1pdm09; Pharmacokinetics; Seasonal influenza
PMID: 32114033 DOI: 10.1016/j.antiviral.2020.104753